Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Diabetic Macular Edema
试验速览
- 阶段
- 3 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Best corrected visual acuity (BCVA)
研究概览
简要总结
Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management
详细描述
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetic macular edema
排除标准
- •other causes of macular edema
- •other macular diseases
研究组 & 干预措施
BEOVU
Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
干预措施: BEOVU intravitreal injection (Drug)
Eylea
Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
干预措施: BEOVU intravitreal injection (Drug)
结局指标
主要结局
Best corrected visual acuity (BCVA)
时间窗: 12 months
Change in BCVA in LOG MARS(logarithm minimum angle of resolution
次要结局
未报告次要终点
研究者
Tarek Roshdy mohamed Mahgoub ELhamaky
Associate Professor
Benha University